Europe - BIT:REC - IT0003828271 - Common Stock
We assign a fundamental rating of 4 out of 10 to REC. REC was compared to 49 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of REC while its profitability can be described as average. REC is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.87% | ||
ROE | 21.77% | ||
ROIC | 12.31% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 26.76% | ||
PM (TTM) | 16.42% | ||
GM | 67.79% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.16 | ||
Debt/FCF | N/A | ||
Altman-Z | 3.65 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.47 | ||
Quick Ratio | 1.01 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 26.81 | ||
Fwd PE | 16.75 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 15.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.33% |
BIT:REC (9/17/2025, 3:29:18 PM)
52.825
-0.17 (-0.33%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.33% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 26.81 | ||
Fwd PE | 16.75 | ||
P/S | 4.46 | ||
P/FCF | N/A | ||
P/OCF | 19.22 | ||
P/B | 5.91 | ||
P/tB | N/A | ||
EV/EBITDA | 15.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.87% | ||
ROE | 21.77% | ||
ROCE | 16.15% | ||
ROIC | 12.31% | ||
ROICexc | 13.4% | ||
ROICexgc | 85.95% | ||
OM | 26.76% | ||
PM (TTM) | 16.42% | ||
GM | 67.79% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.16 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 2.54 | ||
Cap/Depr | 464.32% | ||
Cap/Sales | 35.24% | ||
Interest Coverage | 7.76 | ||
Cash Conversion | 67.5% | ||
Profit Quality | N/A | ||
Current Ratio | 1.47 | ||
Quick Ratio | 1.01 | ||
Altman-Z | 3.65 |